ArticleScientific reports2025
Arising amitraz and pyrethroids resistance mutations in the ectoparasitic Varroa destructor mite in Canada.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Dose-dependent efficacy of a novel dsRNA-based solution containing vadescana for Varroa destructor control.Pest management science · 2026Article
- Behavioral Resistance in Varroa destructor: First Evidence in Response to Acaricide?Archives of insect biochemistry and physiology · 2026Article
- Biological costs and benefits of selective breeding for disease resistance using marker-assisted or field-based selective breeding in honey bees (Apis mellifera).Journal of economic entomology · 2026Article
- Drugs and products in beekeeping: Efficacy and perspectives of natural alternatives.Veterinarni medicina · 2026Review
- Widespread pyrethroid resistance in Varroa destructor in Türkiye: a molecular warning.Experimental & applied acarology · 2026Article
- Evaluation of late-season Varroa destructor treatments and their impact on amitraz resistant mite populations.Scientific reports · 2026Article
- Viruses and vectors tied to honey bee colony losses.PLoS pathogens · 2026Article
- Innate defense mechanisms against Nosema ceranae in hygienic honey bee (Apis mellifera) colonies.PloS one · 2026Article
- Field trials of the novel varroacide, 1-allyloxy-4-propoxybenzene, against Varroa destructor in Western Canada.Scientific reports · 2025Article
- Oxalic acid vaporization: effectiveness against Varroa destructor (Mesostigmata: Varroidae) and safety for Apis mellifera (Hymenoptera: Apidae).Journal of insect science (Online) · 2025Article
- Behavioral and molecular disruptions in honey bees induced by lithium chloride exposure.Scientific reports · 2025Article
- In Vitro Study on the Efficacy of Ziziphus vulgaris L. and Camellia sinensis (L.) Kuntze Extracts for Controlling Varroa destructor (Acari: Varroidae) in Apis mellifera (Hym.: Apidae).Veterinary medicine and science · 2025Article
- Efficacy and Safety of an Oxalic Acid and Glycerin Formulation forPathogens (Basel, Switzerland) · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The ectoparasitic mite Varroa destructor remains a great threat for the beekeeping industry, for example contributing to excessive winter colony loss in Canada. For decades, beekeepers have sequentially used the registered synthetic varroacides tau-fluvalinate, coumaphos, amitraz, and flumethrin, leading to the risk of resistance evolution in the mites. In addition to the widespread resistance to coumaphos and pyrethroids, a decline in amitraz efficacy has recently been reported in numerous beekeeping regions in Canada. The goals of this study were to assess the evolution of resistance to amitraz in Canadian mite populations and to evaluate the presence and incidence of mutations previously associated with resistance to amitraz and pyrethroids in V. destructor. Our bioassay results confirmed the presence of amitraz-resistant mites in the population of Alberta. These phenotypic results were complemented by targeted genotyping of the octopamine receptor gene Octβ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.